Study to evaluate the renal function of adult liver transplant recipients treated with two everolimus-based immunosuppressive regimens (tacrolimus withdrawal vs. minimization) until 12 months post-transplant, with a 6-months follow-up To compare at Month 12 post-transplantation the renal function, measured by estimated GFR (MDRD-4), between tacrolimus withdrawal regimen and early tacrolimus minimization regimen, both facilitated by...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study to evaluate long-term safety of the experimental drug TKI258 in patients with solid tumors who received TKI258 in another study that has completed its primary objective, and who continue to benefit from TKI258 treatment To evaluate long-term safety and tolerability of dovitinib in patients with solid tumors, who are currently receiving treatment with single agent dovitinib within a Novartis sponsored study which has ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

LGX818/MEK162 Combination With Agents (BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma To assess the anti-tumor activity of LGX818/MEK162 in combination with targeted agents after progression on LGX818/MEK162 combination therapy

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study evaluating novel BRAF inhibitor encorafenib (LGX818) when used as single agent in patients with advanced or metastatic BRAF V600 mutant non-small cell lung carcinoma To evaluate the efficacy of LGX818 as measured by Overall Response Rate (ORR) determined by investigator assessment.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A phase I/II multicenter, open-label study of CLR457, administered orally in adult patients with advanced solid malignancies Studio di Fase I/II, multicentrico, in aperto, con CLR457 somministrato per via orale in pazienti adulti con tumori solidi in stadio avanzato 1. To estimate the MTD or RP2D of CLR457 (dose escalation phase) 2. To investigate the anti-tumor activity of CLR457 (Phase II) 1. Valutare la MTD o la RP2D di CLR457 (fase di incremento della d...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A medical follow-up study in patients who received BGG492 for more than 28 days To observe if patients exposed to BGG492 for more than 28 days have developed uterine endometrial stromal sarcomas (females) and/or adrenal cortical adenomas (males and females) at least one year afte...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Extension study to evaluate the long term efficacy, safety and tolerability of secukinumab in patients with rheumatoid arthritis To evaluate the long-term efficacy of secukinumab with respect to ACR20, ACR50 and ACR70 response over time up to Week 260 in subjects with active rheumatoid arthritis who had previously experienced a...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study to provide access to fingolimod to Multiple Sclerosis patients who completed fingolimod phase IIIb studies and who benefited from treatment with fingolimod or do not have suitable alternative treatment options, but do not have access to the reimbursed drug - to provide access to fingolimod to patients who completed local or global fingolimod phase IIIb studies in MS who benefited from treatment with fingolimod or do not have suitable alternative treatme...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A 12-month study to evaluate the efficacy and safety of injections of 0.5 mg ranibizumab into the eye of patients with impaired vision which is caused by new vessels (neovascularization) in the choroid and for which ranibizumab may have a positive impact To demonstrate that intravitreal injection of 0.5 mg ranibizumab, administered based on individual patient needs has superior efficacy compared to sham treatment in adult patients with visual impairme...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune